Guggenheim has recently initiated Twist Bioscience Corp (TWST) stock to Buy rating, as announced on June 4, 2024, according to Finviz. Earlier, on January 17, 2024, Goldman had raised the stock from a Neutral to Buy, setting a price target of $45 for TWST stock. Berenberg also initiated Buy rating with a price target of $27. Additionally, Scotiabank initiated Sector Outperform rating on January 5, 2023, with a target price of $33. Evercore ISI analysts, in their report published on January 3, 2023, also raised their rating and set a price target of $28 for Twist Bioscience Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Twist Bioscience Corp (TWST) Stock Trading Recap
On Tuesday, Twist Bioscience Corp (TWST) stock saw a decline, ending the day at $43.4 which represents a decrease of $-1.78 or -3.94% from the prior close of $45.18. The stock opened at $44.63 and touched a low of $42.35 during the day, reaching a high of $44.91. The volume of shares traded was 0.80 million falling short of the average volume of 0.88 million.
TWST Stock Performance and Moving Averages
In recent trading, Twist Bioscience Corp (TWST) stock price has shown some volatility, fluctuating -6.59% over the last five trades and 0.37% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 31.83%, and it has plunged by -8.28% in the previous three months. Currently, TWST is trading at -1.68%, -6.37%, and 5.21% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, TWST, a Healthcare sector stock, is trading -28.74% below its 52-week high but remains 200.97% above its 52-week low. The Average True Range (ATR) (14 days) of 2.51 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Twist Bioscience Corp’s Profitability and Valuation Ratios
Twist Bioscience Corp’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -63.17% and a profit margin of -74.63%, with a gross margin of 31.83%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Twist Bioscience Corp’s market capitalization stands at $2.54 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 8.61, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 5.17, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 4.26% of Twist Bioscience Corp (TWST)’s shares, while financial institutions hold 106.39%.
Notable insider trades include Finn Patrick John, President and COO at Twist Bioscience Corp (TWST), who sold 2885 shares on Aug 05 ’24, at $39.93 each, totaling $0.12 million. On Aug 05 ’24, Leproust Emily M., Chief Executive Officer, sold 5139 shares for $39.93 each, amounting to $0.21 million. Additionally, on Jul 23 ’24, Finn Patrick John sold 2207 shares at $56.62 each, generating $0.12 million.
